{"id":500,"date":"2026-01-26T14:41:47","date_gmt":"2026-01-26T13:41:47","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/26\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"modified":"2026-02-03T11:03:09","modified_gmt":"2026-02-03T10:03:09","slug":"ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","title":{"rendered":"Ulcerative colitis: Study on the efficacy and safety of risankizumab"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Listings&#8221; module_id=&#8221;target group&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;custom&#8221; background_image_width=&#8221;90%&#8221; background_position=&#8221;bottom_right&#8221; top_divider_height=&#8221;51px&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;3&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|auto|-1px|auto|false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_post_title meta=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#10344C&#8221; title_font_size=&#8221;45px&#8221; custom_margin=&#8221;||15px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_post_title][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;1f09816e-184e-4ce5-a4cf-b39c52c423ca&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#10344C&#8221; text_font_size=&#8221;20px&#8221; text_line_height=&#8221;1.8em&#8221; ul_line_height=&#8221;1.8em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; text_font_size_tablet=&#8221;15px&#8221; text_font_size_phone=&#8221;14px&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; header_font_size_tablet=&#8221;55px&#8221; header_font_size_last_edited=&#8221;off|desktop&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong>ClinicalTrials.gov ID:<\/strong> NCT03398135<br \/><strong>Sponsor:<\/strong> AbbVie Information provided by: AbbVie (responsible party)<\/p>\n<p><strong>Official title:<\/strong><br \/>Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis.<\/p>\n<p><strong>Study overview:<\/strong><br \/>The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded to induction therapy with risankizumab in a previous AbbVie study.<\/p>\n<p>The study consists of three sub-studies and a continuous treatment extension (CTE):<\/p>\n<ul>\n<li>Sub-study 1: 52-week, randomized, double-blind, placebo-controlled maintenance study<\/li>\n<li>Sub-study 2: 52-week, randomized, exploratory maintenance study<\/li>\n<li>Sub-study 3: Open-label long-term extension study for participants who have completed sub-study 1 or 2 or who have responded to induction therapy in study M16-067 but were unable to receive a final endoscopy due to COVID-19 or geopolitical conflicts (Ukraine and affected regions)<\/li>\n<\/ul>\n<p>The CTE serves to ensure continuous treatment with risankizumab until the drug is commercially available or can be obtained locally.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension to evaluate the efficacy and safety of risankizumab in patients with ulcerative colitis. Study overview:The aim is to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who have responded [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-500","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:41:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:03:09+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab\",\"datePublished\":\"2026-01-26T13:41:47+00:00\",\"dateModified\":\"2026-02-03T10:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/\"},\"wordCount\":375,\"articleSection\":[\"Active, recruitment completed\",\"For study partners\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/\",\"name\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\"},\"datePublished\":\"2026-01-26T13:41:47+00:00\",\"dateModified\":\"2026-02-03T10:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ced-study-center-karlshorst\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ulcerative colitis: Study on the efficacy and safety of risankizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/author\\\/paulilauterbachnutzer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","og_locale":"en_US","og_type":"article","og_title":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","og_description":"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-26T13:41:47+00:00","article_modified_time":"2026-02-03T10:03:09+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Ulcerative colitis: Study on the efficacy and safety of risankizumab","datePublished":"2026-01-26T13:41:47+00:00","dateModified":"2026-02-03T10:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"},"wordCount":375,"articleSection":["Active, recruitment completed","For study partners"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/","name":"Ulcerative colitis: Study on the efficacy and safety of risankizumab - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-26T13:41:47+00:00","dateModified":"2026-02-03T10:03:09+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Ulcerative colitis: Study on the efficacy and safety of risankizumab"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=500"}],"version-history":[{"count":3,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500\/revisions"}],"predecessor-version":[{"id":503,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/500\/revisions\/503"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}